Boston Scientific Corporation (NYSE:BSX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Boston Scientific Corporation (NYSE:BSX) have been given an average recommendation of “Moderate Buy” by the thirty-one ratings firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and twenty-four have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $71.6154.

Several brokerages have issued reports on BSX. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. TD Cowen reduced their price target on Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Daiwa Securities Group lowered shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Evercore set a $65.00 price objective on shares of Boston Scientific in a research report on Monday, July 6th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 204,322 shares of company stock valued at $9,939,221. Insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Kelleher Financial Advisors purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at approximately $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the 4th quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new stake in Boston Scientific in the first quarter valued at approximately $28,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 0.1%

BSX opened at $51.77 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company’s 50 day simple moving average is $46.06 and its two-hundred day simple moving average is $59.35. Boston Scientific has a 1-year low of $42.20 and a 1-year high of $109.50. The firm has a market capitalization of $75.02 billion, a price-to-earnings ratio of 20.96, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the business earned $0.75 earnings per share. The business’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts expect that Boston Scientific will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a stock buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its shares are undervalued.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
• Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
• Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
• Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.